New drug cocktail aims to outsmart resistant prostate cancer

NCT ID NCT04986423

Recruiting now Disease control Sponsor: Zenith Epigenetics Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2b trial tests whether adding an experimental drug called ZEN003694 to the standard drug enzalutamide can help men with metastatic castration-resistant prostate cancer that has stopped responding to abiraterone. About 200 men will be randomly assigned to receive either the combination or enzalutamide alone. The study separates patients based on how well they responded to prior abiraterone, and the main goal is to see if the combination delays cancer growth or death.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ZEN003694 (ZEN-3694) combined with enzalutamide (Xtandi)
What this could lead to: If successful, this combination could offer a new treatment option for men with advanced prostate cancer that has stopped responding to standard hormone therapy.
What could go wrong: This is a mid-stage trial with only 200 participants, so results may not confirm benefit. The drug combination may cause side effects or fail to improve progression-free survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Locations

Anhui Provincial Hospital
RECRUITING

Hefei, Anhui, 230002, China
BRCR Global
RECRUITING

Plantation, Florida, 33322, United States
California Research Institute
RECRUITING

Los Angeles, California, 90027, United States
Chongqing Cancer Hospital
RECRUITING

Chongqing, Chongqing Municipality, 400030, China
Colorado Urology
RECRUITING

Lakewood, Colorado, 80228, United States
D&H Cancer Research Center, LLC
RECRUITING

Margate, Florida, 33063, United States
First Hospital of Shanxi Medical University
RECRUITING

Taiyuan, Shanxi, 030001, China
Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 200032, China
Hematology Oncology Clinic
WITHDRAWN

Baton Rouge, Louisiana, 70809, United States
Henan Cancer Hospital
RECRUITING

Zhengzhou, Henan, 450000, China
Hubei Cancer Hospital
RECRUITING

Wuhan, Hubei, 430079, China
Hunan Cancer Hospital
RECRUITING

Changsha, Hunan, 410006, China
Innovative Clinical Research Institute
RECRUITING

Whittier, California, 90603, United States
Liaoning Cancer Hospital
WITHDRAWN

Shenyang, Liaoning, 110042, China
Maryland Oncology Hematology, P.A.
RECRUITING

Columbia, Maryland, 21044, United States
Messino Cancer Center
RECRUITING

Asheville, North Carolina, 28806, United States
Nanjing Drum Tower Hospital
RECRUITING

Nanjing, Jiangsu, 210008, China
Northwest Cancer Specialists, P.C.
RECRUITING

Portland, Oregon, 97223, United States
Seattle Cancer Care Alliance
RECRUITING

Seattle, Washington, 98109, United States
Shanghai Tenth People's Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200072, China
Sichuan Provincial People's Hospital
RECRUITING

Chengdu, Sichuan, 610072, China
Texas Oncology - Central South
RECRUITING

Austin, Texas, 78731, United States
The First Affiliated Hospital of Xi'an Jiaotang University
RECRUITING

Xi'an, Shaanxi, 71000, China
The First Affiliated Hospital of Xiamen University
RECRUITING

Xiamen, Fujian, 361003, China
Tongji Hospital of Tongji Medical College, Huazhong University of Science & Technology
RECRUITING

Wuhan, Hubei, 430030, China
University of California, San Francisco
RECRUITING

San Francisco, California, 94158, United States
University of Michigan Rogel Cancer Center
RECRUITING

Ann Arbor, Michigan, 48109, United States
Urology Associates, P.C.
RECRUITING

Nashville, Tennessee, 37209, United States
Virginia Cancer Specialists
RECRUITING

Fairfax, Virginia, 22031, United States
Weill Cornell Medical College - New York Presbyterian Hospital
COMPLETED

New York, New York, 10065, United States
Zhejiang Provincial People's Hospital
RECRUITING

Hangzhou, Zhejiang, 310014, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.